Home LNA World Healthcare Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers
HealthcareLNA LIFE!Media OutReachPharma

Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers

  • 87% of respondents deemed mRNA a key modality for the future
  • More than 60% vaccine makers surveyed plan revamp or new facilities for mRNA manufacturing to meet demand
  • Skilled personnel, tech-transfer expertise, reliable supply chain, and regulatory guidelines critical to new technology adoption

SINGAPORE 31 May 2023 – According to a recent study sponsored by Merck, a leading science and technology company, mRNA technology is a “game-changer” for Asia-Pacific (APAC) vaccine manufacturers. Nearly 40 manufacturers participated in the survey.

Filling of Merck's synthetic cholesterol, a key component of mRNA-based vaccines and therapeutics, at the company's Darmstadt facility
Filling of Merck’s synthetic cholesterol, a key component of mRNA-based vaccines and therapeutics, at the company’s Darmstadt facility

“Vaccine manufacturers in APAC are looking to build capacity for mRNA technology over the next two to three years, while continuing to produce both traditional and modern cell-based vaccines,” said Josephine Cheng, Senior Consultant, Process Solutions APAC at the Life Science business sector of Merck. “Across APAC, governments are investing and supportive of driving therapeutic discovery and manufacturing. With the range of tools we offer, we can better equip vaccine manufacturers to treat the regional and global population.”

The study interviewed vaccine manufacturers across APAC, including research institutes, pharmaceutical and biotech companies. Eighty-seven percent deemed mRNA a promising technology, expecting it to be a key modality in the future. This is based on the perception that the mRNA platform benefits from shorter development time and templated manufacturing processes, proven efficacy, lower biohazard risk for operators, and flexibility in covering different types of diseases and variants.

Japan, South Korea, Australia, Indonesia, Singapore, China and India are among the markets actively exploring to develop mRNA technology. Over sixty percent of the vaccine makers prefer to revamp or establish new facilities especially for mRNA with expansion planned over the next two to three years.

To effectively move mRNA forward, respondents highlighted the need for skilled personnel trained in these new technologies, tech-transfer expertise, a reliable supply chain, and mRNA-specific regulatory guidelines.

Merck’s contribution to future vaccine manufacturing
Merck’s Life Science business supports mRNA manufacturers helping accelerate speed to market, ensuring safety and efficacy, to reducing complexity across the entire mRNA process to help accelerate delivery of mRNA vaccines to patients worldwide. More information is available on sigmaaldrich.com/vaccines

Related Articles

Advertising, Marketing & Public RelationsLNA WorldMedia OutReach

Green SM reaches the six millionth ride

HANOI, VIETNAM29 September 2023 – Green SM, the pure electric vehicle ride-hailing...

BusinessLNA WorldMedia OutReach

GSM officially launches electric scooter ride-hailing services in Ho Chi Minh City

HO CHI MINH CITY, VIETNAM 29 September 2023 – The Green SM...

BusinessCryptoCurrenciesLNA WorldMedia OutReach

Bybit and Max Verstappen Extend Grand Prix Triumph with Unforgettable Fan Celebration in Japan

DUBAI, UNITED ARAB EMIRATES 29 September 2023 – Bybit, the world’s third...

BusinessLifestyle, Fashion & WellnessLNA WorldMedia OutReach

Spectacular Gala Evening marks opening of ‘TIMELESS Watch Week’ at LANDMARK

Exceptional showcase of prestigious Grand Prix d’Horlogerie de Genève awardees, horological masterclasses...